Medical Nitrous Oxide Market Report 2026

The medical nitrous oxide market size has grown strongly in recent years. It will grow from $2.34 billion in 2025 to $2.56 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to widespread use in dental anesthesia, growth in surgical procedures, established role in pain management, increasing hospital infrastructure, long-standing clinical acceptance.

The medical nitrous oxide market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising demand for non-opioid analgesics, expansion of outpatient and ambulatory care, growth in emergency medical services, increasing focus on patient comfort and anxiety reduction, stricter regulations supporting medical gas standardization. Major trends in the forecast period include growing use of nitrous oxide in minimally invasive procedures, rising adoption in dental and outpatient care settings, increasing demand for safe and controlled pain management, expansion of emergency and trauma care services, greater emphasis on medical gas quality and purity standards.

The growing demand for pain management is expected to propel the growth of the medical nitrous oxide market going forward. Pain management is a medical discipline focused on reducing or eliminating pain through medications, therapeutic interventions, and clinical procedures. Demand for pain management is rising due to the increasing prevalence of chronic pain, aging populations, and advancements in medical technologies that expand treatment accessibility and effectiveness. The medical nitrous oxide market supports this trend by providing rapid analgesia and sedation during medical and dental procedures, reducing pain perception with minimal side effects and enabling quick patient recovery. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a U.S.-based government agency, 24.3% of U.S. adults experienced chronic pain in 2023, and 8.5% reported high-impact chronic pain that frequently limited life or work activities. Therefore, the growing demand for pain management is driving the growth of the medical nitrous oxide market.

Major companies operating in the medical nitrous oxide market are focusing on developing technological innovations such as advanced drug delivery systems to enhance precision, safety, and efficiency in nitrous oxide administration for clinical use. Advanced drug delivery systems refer to specialized technologies engineered to deliver therapeutic gases or medications with controlled accuracy, ensuring optimal dosing, improved patient outcomes, and greater compliance in various medical settings. For instance, in December 2023, Mallinckrodt plc, an Ireland-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) clearance for its INOmax EVOLVE DS delivery system, designed to administer INOmax (nitric oxide) gas for inhalation. The system features an advanced injector module that provides consistent nitric oxide concentration synchronized throughout the breath cycle and is validated for use with compatible ventilators and respiratory devices, supporting safe and precise delivery during respiratory therapy.

In May 2025, BeaconMedaes Australia, an Australia-based provider of medical gas systems, partnered with Medclair AB to integrate Medclair’s nitrous oxide purification technology, including its Central Destruction Unit and Mobile Destruction Unit into BeaconMedaes’ medical gas solutions, enhancing patient care, improving workplace safety, and significantly reducing the environmental impact of medical nitrous oxide use in healthcare facilities the partnership strengthens BeaconMedaes’ sustainability-focused offerings while expanding Medclair’s reach in hospital and clinic settings. Medclair AB is a Sweden-based company developing sustainable nitrous oxide management systems for safe and environmentally responsible medical use.

Major companies operating in the medical nitrous oxide market are Linde plc, Air Liquide, Air Products and Chemicals Inc., Taiyo Nippon Sanso Corporation, Messer SE & Co KGaA, Gulf Cryo, Earlbeck Gases & Technology, BOC Healthcare, nexAir LLC, Matheson Tri‑Gas Inc., SOL SpA, Southern Gas Limited, Norco Inc., Ellenbarrie Industrial Gases Ltd., CalOx Inc., Oxygen & Argon Works Ltd., Chengdu Taiyu Industrial Gases Co Ltd, Jiangsu Huazhong Gas Co Ltd, Steelman Gases Pvt Ltd, Axcel Gases, Baldus Sedation GmbH & Co KG, Analgesic Services Inc, IJsfabriek Strombeek nv, Keen Compressed Gas Co, Middle East Industries Gases Co.

North America was the largest region in the medical nitrous oxide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical nitrous oxide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical nitrous oxide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs influence the medical nitrous oxide market by increasing costs associated with gas production equipment, storage cylinders, and cross-border distribution. Hospitals and dental clinics in north america, europe, and parts of asia-pacific are most affected due to reliance on imported cylinders and purification systems. Higher tariffs may raise procurement costs and slow adoption in smaller facilities. However, they also encourage local manufacturing and regional supply development, improving long-term supply stability.

The medical nitrous oxide market research report is one of a series of new reports that provides medical nitrous oxide market statistics, including medical nitrous oxide industry global market size, regional shares, competitors with a medical nitrous oxide market share, detailed medical nitrous oxide market segments, market trends and opportunities, and any further data you may need to thrive in the medical nitrous oxide industry. This medical nitrous oxide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical nitrous oxide is a colorless, non-flammable gas utilized in healthcare for anesthesia, pain management, and surgical procedures. Commonly referred to as laughing gas, it is employed in dentistry, surgery, and emergency care to alleviate pain and reduce anxiety.

The primary forms of medical nitrous oxide are gaseous and liquid states. Gaseous medical nitrous oxide is a colorless, non-flammable anesthetic gas used for pain relief and sedation during medical and dental procedures. It is categorized by purity levels into medium grade (98%-99%), A-Z grade (99.9%), and low grade (below 98%). Depending on its application, medical nitrous oxide is used in cryosurgery, surgical insufflation, and anesthesia for pain management. It serves a variety of end users, including dental clinics, emergency medical services, the food industry, hospitals, research laboratories, and veterinary clinics.

The medical nitrous oxide market consists of sales of pure medical nitrous oxide (N₂O), nitrous oxide-oxygen mixture, and pre-mixed nitrous oxide for medical use. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.